These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
452 related articles for article (PubMed ID: 11718214)
1. Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment? Clavio M; Quintino S; Venturino C; Ballerini F; Varaldo R; Gatto S; Galbusera V; Garrone A; Grasso R; Canepa L; Miglino M; Pierri I; Gobbi M J Exp Clin Cancer Res; 2001 Sep; 20(3):351-8. PubMed ID: 11718214 [TBL] [Abstract][Full Text] [Related]
2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
3. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Marcus R; Hagenbeek A Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982 [TBL] [Abstract][Full Text] [Related]
4. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [TBL] [Abstract][Full Text] [Related]
5. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020 [TBL] [Abstract][Full Text] [Related]
6. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma. Bosly A; Keating MJ; Stasi R; Bradstock K Anticancer Drugs; 2002 Nov; 13 Suppl 2():S25-33. PubMed ID: 12710588 [TBL] [Abstract][Full Text] [Related]
7. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond. Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077 [TBL] [Abstract][Full Text] [Related]
10. [Use of Mabtera (rituximab) in treating patients with refractory courses of B-cell lymphoma, along with high-dose chemotherapy and autologous transplantation of hematopoietic stem cells]. Ptushkin VV; Chimishkian KL; Zhukov NV; Osmanov DSh; Andreeva LIu; Tupitsyn NN; Larionova VB; Mkheidze DM; Poddubnaia NV Ter Arkh; 2003; 75(1):65-8. PubMed ID: 12652962 [TBL] [Abstract][Full Text] [Related]
11. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma]. Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560 [TBL] [Abstract][Full Text] [Related]
12. Rituximab for the treatment of diffuse large B-cell lymphomas. Held G; Pöschel V; Pfreundschuh M Expert Rev Anticancer Ther; 2006 Aug; 6(8):1175-86. PubMed ID: 16925484 [TBL] [Abstract][Full Text] [Related]
13. B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenström's macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders. Pangalis GA; Angelopoulou MK; Vassilakopoulos TP; Siakantaris MP; Kittas C Semin Hematol; 1999 Apr; 36(2):104-14. PubMed ID: 10319379 [TBL] [Abstract][Full Text] [Related]
15. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies. Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379 [TBL] [Abstract][Full Text] [Related]
16. Autologous and allogeneic stem cell transplantation in Waldenstrom's macroglobulinemia: review of the literature and future directions. Anagnostopoulos A; Aleman A; Giralt S Semin Oncol; 2003 Apr; 30(2):286-90. PubMed ID: 12720154 [TBL] [Abstract][Full Text] [Related]
17. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma. Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245 [TBL] [Abstract][Full Text] [Related]
18. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas. Voulgarelis M; Giannouli S; Anagnostou D; Tzioufas AG Rheumatology (Oxford); 2004 Aug; 43(8):1050-3. PubMed ID: 15187246 [TBL] [Abstract][Full Text] [Related]
19. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Davis TA; Czerwinski DK; Levy R Clin Cancer Res; 1999 Mar; 5(3):611-5. PubMed ID: 10100713 [TBL] [Abstract][Full Text] [Related]
20. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma]. Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]